Alvotech Resolves Global Patent Disputes for Eylea Biosimilar, Clearing Path for 2026 Launches
Event summary
- Alvotech reached a global settlement with Regeneron and Bayer, resolving all patent disputes related to its biosimilar to Eylea® 2mg (aflibercept).
- The agreement allows Alvotech to market and sell the biosimilar in the UK and Canada starting January 1, 2026, and in Japan (excluding diabetic macular edema) starting May 1, 2026.
- The biosimilar is approved under the tradenames Mynzepli® and Afiveg® in the European Economic Area and the UK, and as Aflibercept BS in Japan.
- Alvotech's commercial partners for the Eylea biosimilar include Advanz Pharma, STADA, Biogaran in Europe, and Fuji Pharma Ltd. in Japan.
The big picture
The settlement clears the way for Alvotech to challenge Regeneron and Bayer's Eylea® in key global markets, a move that could intensify competition in the retinal disease treatment space. The biosimilar market continues to expand as patent expirations open opportunities for cost-effective alternatives, but success will depend on Alvotech's ability to navigate regulatory hurdles and establish strong commercial footprints.
What we're watching
- Market Penetration
- How Alvotech's biosimilar will compete with Eylea® in key markets like Europe and Japan, given the established dominance of the original drug.
- Regulatory Execution
- Whether Alvotech can secure U.S. regulatory approval by Q4 2026, as previously announced, to fully capitalize on global market opportunities.
- Commercial Strategy
- The effectiveness of Alvotech's partnerships with regional commercial players in driving market adoption and revenue growth.
Related topics